

CHARLES RIVER LABORATORIES INTERNATIONAL INC  
Form 8-K  
February 11, 2009

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

February 9, 2009

Charles River Laboratories International, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-15943

06-1397316

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

251 Ballardvale St., Wilmington,  
Massachusetts

01887

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

978-658-6000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 2.05 Costs Associated with Exit or Disposal Activities.**

As part of a realignment of our infrastructure intended to enhance our operating efficiencies, on February 9, 2009 Charles River Laboratories International, Inc. (the "Company") announced that it has decided to undertake a number of actions in the first quarter of 2009. Included in these actions is the commitment to close the Company's Preclinical Services site in Arkansas by the end of 2009. The closure is expected to result in a one-time write-off of approximately \$5.4 million, which consists of cash severance payments to employees of approximately \$2.2 million, as well as a write-off of approximately \$3.2 million related to the disposition of the associated real property. The Company expects these charges to be recorded primarily in the first quarter of 2009.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Charles River Laboratories International, Inc.

*February 11, 2009*

By: *Matthew L. Daniel*

---

*Name: Matthew L. Daniel*

*Title: Senior Corporate Counsel and Assistant Secretary*